{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:01:39Z","timestamp":1783116099529,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.virol.2020.02.005","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T09:51:40Z","timestamp":1582537900000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice"],"prefix":"10.1016","volume":"545","author":[{"given":"Qiong-Qiong","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Juan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ju","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Jiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2020.02.005_bib1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2020.02.005_bib2","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2020.02.005_bib3","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMra1000449","article-title":"Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection","volume":"362","author":"Bautista","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2020.02.005_bib4","series-title":"Combination therapy with oseltamivir and favipiravir delays mortality but does not prevent oseltamivir resistance in immunodeficient mice infected with pandemic A(H1N1) influenza virus","author":"Baz","year":"2018"},{"key":"10.1016\/j.virol.2020.02.005_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/irv.12176","article-title":"Detection and management of antiviral resistance for influenza viruses","volume":"7","author":"Boivin","year":"2013","journal-title":"Influenza Other Respi. Viruses"},{"key":"10.1016\/j.virol.2020.02.005_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.antiviral.2013.08.023","article-title":"Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance","volume":"100","author":"Burnham","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2020.02.005_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3851\/IMP2672","article-title":"Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir","volume":"23","author":"Cao","year":"2014","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2020.02.005_bib9","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jac\/dky462","article-title":"Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection","volume":"74","author":"Fukao","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2020.02.005_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib13","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.virol.2020.02.005_bib14","first-page":"337","article-title":"Baloxavir and treatment-emergent resistance: public health insights and next steps","volume":"221","author":"Gubareva","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.virol.2020.02.005_bib15","first-page":"60","article-title":"Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respi","volume":"7","author":"Ison","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2020.02.005_bib16","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1128\/AAC.00709-16","article-title":"Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters","volume":"60","author":"Jochmans","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02460-16","article-title":"The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses","volume":"61","author":"Jones","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183319","article-title":"Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer","volume":"12","author":"Jovelet","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2020.02.005_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/v10020072","article-title":"Favipiravir and ribavirin inhibit replication of asian and african strains of Zika virus in different cell models","volume":"10","author":"Kim","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2020.02.005_bib20","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2020.02.005_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/651083","article-title":"Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection","volume":"50","author":"Ling","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2020.02.005_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coviro.2014.03.001","article-title":"H7N9: a low pathogenic avian influenza A virus infecting humans","volume":"5","author":"Liu","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.virol.2020.02.005_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bdq.2016.10.002","article-title":"Three-color crystal digital PCR","volume":"10","author":"Madic","year":"2016","journal-title":"Biomol Detect Quantif"},{"key":"10.1016\/j.virol.2020.02.005_bib24","article-title":"Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice","volume":"9","author":"Manicassamy","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2020.02.005_bib25","doi-asserted-by":"crossref","first-page":"26742","DOI":"10.1038\/srep26742","article-title":"Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice","volume":"6","author":"Marathe","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2020.02.005_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/irv.12258","article-title":"Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status","volume":"8","author":"Matias","year":"2014","journal-title":"Influenza Other Respi. Viruses"},{"key":"10.1016\/j.virol.2020.02.005_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004364","article-title":"A rapid screening assay identifies monotherapy with interferon-ss and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus","volume":"10","author":"McCarthy","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.virol.2020.02.005_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nrmicro2613","article-title":"Influenza A viruses: new research developments","volume":"9","author":"Medina","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2020.02.005_bib29","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2020.02.005_bib30","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/jac\/dky560","article-title":"Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model","volume":"74","author":"Pascua","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib31","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.virol.2020.02.005_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2020.02.005_bib33","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.01739-09","article-title":"In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses","volume":"54","author":"Sleeman","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice","volume":"54","author":"Smee","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib35","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2217\/fvl.13.98","article-title":"Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice","volume":"8","author":"Smee","year":"2013","journal-title":"Future Virol."},{"key":"10.1016\/j.virol.2020.02.005_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/095632020301400502","article-title":"In vitro and in vivo activities of T-705 and oseltamivir against influenza virus","volume":"14","author":"Takahashi","year":"2003","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.virol.2020.02.005_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104718","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018","volume":"175","author":"Takashita","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2020.02.005_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir","volume":"132","author":"Takashita","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2020.02.005_bib39","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800698","article-title":"Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill."},{"key":"10.1016\/j.virol.2020.02.005_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2020.02.005_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/nyas.12462","article-title":"Continuing challenges in influenza","volume":"1323","author":"Webster","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.virol.2020.02.005_bib43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coviro.2016.05.004","article-title":"Current and novel antiviral strategies for influenza infection","volume":"18","author":"Yen","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.virol.2020.02.005_bib44","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/JCM.01532-09","article-title":"Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A\/H1N1 viruses","volume":"48","author":"Zaraket","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.virol.2020.02.005_bib45","first-page":"e78","article-title":"Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution","volume":"3","author":"Zhang","year":"2014","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.virol.2020.02.005_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.antiviral.2019.02.017","article-title":"A novel RSV F-Fc fusion protein vaccine reduces lung injury induced by respiratory syncytial virus infection","volume":"165","author":"Zhang","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2020.02.005_bib47","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/22221751.2019.1635873","article-title":"Mammalian-adaptive mutation NP-Q357K in Eurasian H1N1 Swine Influenza viruses determines the virulence phenotype in mice","volume":"8","author":"Zhu","year":"2019","journal-title":"Emerg. Microb. Infect."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682220300350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682220300350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:50:32Z","timestamp":1758588632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682220300350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":46,"alternative-id":["S0042682220300350"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2020.02.005","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2020.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}